Reported about 19 hours ago
Novo Holdings plans to double the size of Catalent, its recently acquired contract drugmaker, over the next five years, anticipating a focus on U.S. manufacturing under President-elect Donald Trump. Following a $16.5 billion acquisition, Novo sold Catalent's plants to bolster Novo Nordisk’s production of Wegovy. As Trump is expected to prioritize American manufacturing and impose tariffs on China, there's potential for increased reliance on domestic contract manufacturers like Catalent and Thermo Fisher's Patheon.
Source: YAHOO